| Code | 4996E | ||||||||||
| MA number | 44/0259/23-S | ||||||||||
| Product Form: | con inf 1x4 ml/100 mg (liek.inj.skl.jantárová) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Accord Healthcare Polska Sp. z o.o., Poland | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | glass vial | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(3) hybrid application |
| MA issued: | 04.01.2024 |
| Validity: | 04.01.2029 |
| SPC: |
SPC_Bendamustine Accord 25 mg_ml koncentrát na infúzny roztok_11.2024.pdf
|
| PIL: |
PIL_Bendamustine Accord 25 mg_ml koncentrát na infúzny roztok_11.2024.pdf
|
| Safety feature | Yes |
| Data update: | 28.03.2024 |
